NewAmsterdam Pharma Co. NV (NAMS)
27.09
-0.25
(-0.91%)
USD |
NASDAQ |
Aug 26, 12:22
NewAmsterdam Pharma Debt to Equity Ratio : 0.0001 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0001 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.0003 |
| September 30, 2025 | 0.0004 |
| June 30, 2025 | 0.0004 |
| March 31, 2025 | 0.0005 |
| December 31, 2024 | 0.0006 |
| September 30, 2024 | 0.0013 |
| June 30, 2024 | 0.0015 |
| Date | Value |
|---|---|
| March 31, 2024 | 0.0001 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ProQR Therapeutics NV | 0.166 |
| Pharming Group NV | 0.4931 |
| argenx SE | -- |
| Arcutis Biotherapeutics, Inc. | 0.5174 |
| Damora Therapeutics, Inc. | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 704.45M |
| Total Liabilities (Quarterly) | 73.03M |
| Shareholders Equity (Quarterly) | 631.42M |
| Current Ratio | 9.034 |
| Net Debt Paydown Yield | 0.00% |